Benjamin Blasco

Benjamin Blasco

Auto-generated profile, based on publicly available information

Benjamin Blasco

Global Antibiotic Research & Development Partnership (GARDP), Chemin Camille-Vidart 15, 1202 Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
UTUrsula Theuretzbacher
Ursula Theuretzbacher
BBBenjamin Blasco
Benjamin Blasco
MDMaëlle Duffey
Maëlle Duffey
LPLaura Piddock
Laura Piddock

25 April 2024 in ACS Infectious Diseases
Verified
Journal Article
Open access
MDMaëlle Duffey
Maëlle Duffey
RJRavindra P. Jumde
Ravindra P. Jumde
RCRenata M.A. da Costa
Renata M.A. da Costa
HRHenni-Karoliina Ropponen
Henni-Karoliina Ropponen
BBBenjamin Blasco
Benjamin Blasco
LPLaura Piddock
Laura Piddock
Efflux is a natural process found in all prokaryotic and eukaryotic cells that removes a diverse range of substrates from inside to outside. Many antibiotics are substrates of bacterial efflux pumps, and modifications to the structure or overexpression of efflux pumps are an important resistance mechanism utilized by many multidrug-resistant bacteria. Therefore, chemical inhibition of bacterial efflux to revitalize existing antibiotics has been considered a promising approach for antimicrobial chemotherapy over two decades, and various strategies have been employed. In this review, we provide an overview of bacterial multidrug resistance (MDR) efflux pumps, of which the resistance nodulation division (RND) efflux pumps are considered the most clinically relevant in Gram-negative bacteria, and describe over 50 efflux inhibitors that target such systems. Although numerous efflux inhibitors have been identified to date, none have progressed into clinical use because of formulation, toxicity, and pharmacokinetic issues or a narrow spectrum of inhibition. For these reasons, the development of efflux inhibitors has been considered a difficult and complex area of research, and few active preclinical studies on efflux inhibitors are in progress. However, recently developed tools, including but not limited to computational tools including molecular docking models, offer hope that further research on efflux inhibitors can be a platform for research and development of new bacterial efflux inhibitors.

21 July 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
JMJames M. Murithi
James M. Murithi
CPCécile Pascal
Cécile Pascal
JBJade Bath
Jade Bath
XBXavier Boulenc
Xavier Boulenc
NGNina F. Gnädig
Nina F. Gnädig
DLDidier Leroy
Didier Leroy
We report an acylguanidine preclinical candidate with pharmacological features compatible with single low-dose malaria cure.

22 March 2024 in EBioMedicine
Verified
Journal Article
Open access
BBBenjamin Blasco
Benjamin Blasco
SJSoojin Jang
Soojin Jang
HTHiroki Terauchi
Hiroki Terauchi
NKNaoki Kobayashi
Naoki Kobayashi
SSShuichi Suzuki
Shuichi Suzuki
LPLaura Piddock
Laura Piddock
The current pipeline for new antibiotics fails to fully address the significant threat posed by drug-resistant Gram-negative bacteria that have been identified by the World Health Organization (WHO) as a global health priority. New antibacterials acting through novel mechanisms of action are urgently needed. We aimed to identify new chemical entities (NCEs) with activity against Klebsiella pneumoniae and Acinetobacter baumannii that could be developed into a new treatment for drug-resistant infections. We developed a high-throughput phenotypic screen and selection cascade for generation of hit compounds active against multidrug-resistant (MDR) strains of K. pneumoniae and A. baumannii. We screened compound libraries selected from the proprietary collections of three pharmaceutical companies that had exited antibacterial drug discovery but continued to accumulate new compounds to their collection. Compounds from two out of three libraries were selected using “eNTRy rules” criteria associated with increased likelihood of intracellular accumulation in Escherichia coli. We identified 72 compounds with confirmed activity against K. pneumoniae and/or drug-resistant A. baumannii. Two new chemical series with activity against XDR A. baumannii were identified meeting our criteria of potency (EC50 ≤50 μM) and absence of cytotoxicity (HepG2 CC50 ≥100 μM and red blood cell lysis HC50 ≥100 μM). The activity of close analogues of the two chemical series was also determined against A. baumannii clinical isolates. This work provides proof of principle for the screening strategy developed to identify NCEs with antibacterial activity against multidrug-resistant critical priority pathogens such as K. pneumoniae and A. baumannii. The screening and hit selection cascade established here provide an excellent foundation for further screening of new compound libraries to identify high quality starting points for new antibacterial lead generation projects. BMBF and GARDP.

15 May 2014 in Journal of Bacteriology
Verified
Journal Article
Open access
PDF file
BBBenjamin Blasco
Benjamin Blasco
AJAleksandre Japaridze
Aleksandre Japaridze
MSMarco Stenta
Marco Stenta
BWBasile I. M. Wicky
Basile I. M. Wicky
GDGiovanni Dietler
Giovanni Dietler
SCStewart T. Cole
Stewart T. Cole
The nucleoid-associated protein EspR, a chromosome organizer, has pleiotropic effects on expression of genes associated with cell wall function and pathogenesis in Mycobacterium tuberculosis . In particular, EspR binds to several sites upstream of the espACD locus to promote its expression, thereby ensuring full function of the ESX-1 secretion system, a major virulence determinant. The N terminus of EspR contains the helix-turn-helix DNA-binding domain, whereas the C-terminal dimerization domain harbors residues involved in intersubunit interactions. While direct binding to DNA appears to be mediated by an EspR dimer-of-dimers, where two helix-turn-helix motifs remain free for long-range interactions, the mechanism of EspR higher-order organization and its impact on chromosome structure and gene expression are not understood. To investigate these processes, we identified seven amino acid residues using molecular dynamics and replaced them with Ala in order to probe interactions at either the dimer or the dimer-of-dimers interfaces. Arg70, Lys72, and Arg101 were important for protein stability and optimal DNA-binding activity. Moreover, the Arg70 mutant showed decreased dimerization in a mycobacterial two-hybrid system. To correlate these defects with higher-order organization and transcriptional activity, we used atomic force microscopy to observe different EspR mutant proteins in complex with the espACD promoter region. In addition, complementation of an M. tuberculosis espR knockout mutant was performed to measure their impact on EspA expression. Our results pinpoint key residues required for EspR function at the dimer (Arg70) and the dimer-of-dimers (Lys72) interface and demonstrate that EspR dimerization and higher-order oligomerization modulate espACD transcriptional activity and hence pathogenesis.

21 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NBNicolas M. B. Brancucci
Nicolas M. B. Brancucci
CGChristin Gumpp
Christin Gumpp
GGGeert-Jan van Gemert
Geert-Jan van Gemert
XYXiao Yu
Xiao Yu
APArmin Passecker
Armin Passecker
TVTill S. Voss
Till S. Voss
Elimination and eradication of malaria will depend on new drugs with potent activity against Plasmodium falciparum mature stage V gametocytes, the only stages able to infect the mosquito vector for onward parasite transmission. The identification of molecules active against these quiescent stages is difficult due to the specific biology of gametocyte maturation and challenges linked to their cultivation in vitro . Furthermore, the antimalarial drug development pipeline lacks a suitable animal model for evaluating the transmission-blocking potential of promising lead compounds and preclinical and clinical drug candidates in vivo . Here, we established a transmission-blocking drug discovery and development platform based on transgenic P. falciparum parasites engineered to produce large numbers of pure stage V gametocytes expressing a red-shifted firefly luciferase as reporter for cellular viability. This NF54/iGP1_RE9H ulg8 line facilitated the development of a highly efficient and robust in vitro screening assay for the identification of stage V gametocytocidal compounds. Importantly, by infecting humanized NODscidIL2Rγ null mice with pure NF54/iGP1_RE9H ulg8 stage V gametocytes, we also established a preclinical P. falciparum in vivo transmission model. Using whole animal bioluminescence imaging and quantification of gametocyte densities over a period of 14 days, we assessed the gametocyte killing and clearance kinetics in vivo of antimalarial reference drugs as well as five clinical drug candidates and identified markedly different pharmacodynamic response profiles. Furthermore, we successfully integrated this mouse model with mosquito feeding assays and thus firmly established a valuable tool for the systematic in vivo evaluation of gametocytocidal and transmission-blocking drug efficacy. One sentence summary: We applied robust new assays for gametocytocidal drug discovery and in vivo efficacy testing using a humanized mouse model for malaria transmission